Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01752855 · ClinicalTrials.gov registry record · Phase 2

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

A Phase 2 study of Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT01752855 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 88 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01752855, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • BIOLOGICAL New formulation adalimumab

Study Locations (20)

Other

  • Site Reference ID/Investigator# 92053 - Brussels
  • Site Reference ID/Investigator# 92054 - Liège
  • Site Reference ID/Investigator# 91954 - Brno
  • Site Reference ID/Investigator# 91955 - Prague
  • Site Reference ID/Investigator# 91953 - Uherské Hradiště
  • Site Reference ID/Investigator# 91956 - Zlín
  • Site Reference ID/Investigator# 92073 - Ratingen
  • Site Reference ID/Investigator# 92074 - Vega Baja
  • Site Reference ID/Investigator# 92093 - Bucharest
  • Site Reference ID/Investigator# 92095 - Cluj-Napoca
  • Site Reference ID/Investigator# 92094 - Ploieşti
  • Site Reference ID/Investigator# 92096 - Banská Bystrica
  • Site Reference ID/Investigator# 92097 - Senica
  • Site Reference ID/Investigator# 92098 - Žilina

Arizona

  • Site Reference ID/Investigator# 92113 - Mesa

California

  • Site Reference ID/Investigator# 92118 - Hemet

Kansas

  • Site Reference ID/Investigator# 92117 - Wichita

New Jersey

  • Site Reference ID/Investigator# 92115 - Clifton

Pennsylvania

  • Site Reference ID/Investigator# 92116 - Philadelphia

South Carolina

  • Site Reference ID/Investigator# 92114 - Charleston

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2012-12
Est. Completion 2013-10
Phase Phase 2

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01752855

The ClinicalTrials.gov registry entry for NCT01752855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which New formulation adalimumab is the first listed.

NCT01752855 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT01752855 about?

NCT01752855 is a clinical study titled "Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab". A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.

What is the current status of trial NCT01752855?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2012-12. Estimated completion is 2013-10.

What conditions does trial NCT01752855 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01752855?

The interventions under investigation include: New formulation adalimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT01752855?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01752855 being conducted?

This trial has 20 study locations across Arizona, California, Kansas, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.